Chiesi and Epigenesis enter license and development agreement for antisense oligonucleotide treatment of asthma.(Chiesi Farmaceutici, S.p.A., Epigenesis ... : An article from: BIOTECH Patent News

Chiesi and Epigenesis enter license and development agreement for antisense oligonucleotide treatment of asthma.(Chiesi Farmaceutici, S.p.A., Epigenesis ... : An article from: BIOTECH Patent News Offer Price: USD $5.95 See Latest Price & Discount Binding: Digital Publication Date: 2000-01-01 Publisher:Biotech Patent News Editorial Reviews: Book Description This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on January 1, 2000. The length of the article is 544 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Chiesi and Epigenesis enter license and development agreement for antisense oligonucleotide treatment of asthma.(Chiesi Farmaceutici, S.p.A., Epigenesis Pharmaceuticals Inc.)(Brief Article) Publication:BIOTECH Patent News (Newsletter) Date: January 1, 2000 Publisher: Biotech Patent News Volume: 14 Issue: 1 Page: NA Article Type: Brief Article Distributed by Thomson Gale